Hani Kushlaf, MD
Neurology · Cincinnati, OHNPI 1215190590
Payments from drug & device makers
Across 312 payments — averaging $5941.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$641K
- Amicus Therapeutics, Inc.$434K
- Novartis$235K
- AstraZeneca$180K
- Sanofi US Services Inc.$68K
- Catalyst Pharmaceuticals, Inc.$56K
- plus $239K from 14 others
Across 47 payments — averaging $220.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$6K
- Regeneron$2K
- Shire North American Group Inc$2K
- AstraZeneca$770
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 92 | $641,127 |
| Amicus Therapeutics, Inc. | 45 | $434,401 |
| Novartis | 6 | $235,126 |
| AstraZeneca(2 entities) | 28 | $180,107 |
| Sanofi US Services Inc. | 2 | $68,190 |
| Catalyst Pharmaceuticals, Inc. | 18 | $56,308 |
| Amgen(2 entities) | 5 | $49,353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $38,038 |
| Harmony Biosciences LLC | 2 | $35,513 |
| Regeneron | 4 | $29,062 |
| Sarepta Therapeutics, Inc. | 27 | $26,249 |
| Argenx US, Inc. | 15 | $17,580 |
| UCB, Inc. | 22 | $17,509 |
| Janssen Research & Development, LLC | 9 | $16,126 |
| Akcea Therapeutics, Inc. | 17 | $7,380 |
| ITF Therapeutics LLC | 3 | $1,521 |
| Eisai Inc. | 1 | $125 |
| PTC Therapeutics, Inc. | 1 | $68 |
| Biogen | 1 | $48 |
| Sanofi-aventis U.S. LLC | 1 | $37 |
How this compares
$1,853,866 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Cincinnati
- Aram ZabetiCincinnati$5.3M
- Alberto EspayCincinnati$785K
- Brandon ForemanCincinnati$677K
- Andrew DukerCincinnati$620K
- Michelle BowmanCincinnati$419K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.